Surmodics INC 8-K filings

Surmodics, Inc. has completed its merger with BCE Parent, LLC, becoming a private entity with shareholders receiving $43.00 per share in cash.

A U.S. District Court denied the FTC's request for a preliminary injunction, moving Surmodics' proposed acquisition by GTCR closer to completion.

Surmodics reports mixed third-quarter fiscal 2025 financial results, with growth in Pounce Thrombectomy and IVD segments offset by declines in SurVeil DCB revenue, while updating full-year guidance amidst ongoing FTC merger litigation.

Surmodics, Inc. announced a cyber incident involving unauthorized access to its IT systems, but reports critical systems are restored and customer operations remain uninterrupted.

Surmodics announced its Q2 fiscal year 2025 financial results, revealing a revenue decrease and GAAP loss, while also introducing financial guidance for the remainder of the fiscal year, all while navigating a pending acquisition by GTCR and related FTC litigation.

The FTC has filed a complaint to block the proposed acquisition of Surmodics by GTCR due to concerns about its potential impact on competition.

Surmodics, Inc. held its annual shareholder meeting on February 6, 2025, and shareholders voted on the election of a director, setting the number of directors, ratification of the appointment of Deloitte & Touche LLP, and an advisory vote on executive compensation.

Surmodics reported a slight revenue decrease and a larger net loss for the first quarter of fiscal year 2025, while navigating a pending acquisition by GTCR.

Surmodics announced a 19% year-over-year increase in total revenue for the fourth quarter of fiscal year 2024, driven by strong performance in its Medical Device segment, while also reporting a net loss due to merger-related expenses.

Surmodics, Inc. shareholders voted to approve the merger agreement with BCE Parent, LLC at a special meeting held on August 13, 2024.

Surmodics and its merger partner received a second request for information from the Federal Trade Commission, extending the waiting period for their proposed merger.

Surmodics, Inc. announces the resignation of director Ronald B. Kalich due to health reasons, effective August 4, 2024.

Surmodics reported a decrease in total revenue due to a significant drop in license fee revenue, but saw growth in other areas, while also announcing a pending acquisition by GTCR.

Surmodics, a medical device and in vitro diagnostics company, has agreed to be acquired by GTCR for $43.00 per share in cash, valuing the company at approximately $627 million.

Surmodics reported strong second-quarter results, driven by medical device sales and the launch of two new thrombectomy devices, leading to an increase in full-year financial guidance.

Surmodics, Inc. held its annual shareholder meeting on February 8, 2024, where directors were elected and proposals were approved, including setting the number of directors at six and ratifying the appointment of Deloitte & Touche LLP as the company's independent auditor.

Surmodics reported a strong first quarter with a 23% increase in total revenue and has raised its full-year financial guidance.